We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+6.96%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.16B
AUM Growth
+$312M
Cap. Flow
+$49.6M
Cap. Flow %
1.19%
Top 10 Hldgs %
18.39%
Holding
702
New
49
Increased
376
Reduced
176
Closed
46

Top Sells

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$26.9M
2
YHOO
Yahoo Inc
YHOO
+$20.9M
3
EMC
EMC CORPORATION
EMC
+$19.1M
4
CBRE icon
CBRE Group
CBRE
+$15.9M
5
INTC icon
Intel
INTC
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 25.52%
2 Financials 12.75%
3 Technology 11.83%
4 Communication Services 9.9%
5 Consumer Staples 8.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADM icon
401
Archer Daniels Midland
ADM
$41.4B
$1.49M 0.04%
35,301
+13,451
+62% +$582K
ZGNX
402
DELISTED
Zogenix, Inc.
ZGNX
$1.49M 0.04%
130,000
+25,000
+24% +$231K
TSM icon
403
TSMC
TSM
$2.09T
$1.47M 0.04%
48,125
+1,125
+2% +$32.2K
NLY icon
404
Annaly Capital Management
NLY
$16.9B
$1.47M 0.04%
34,877
+1,867
+6% +$80.9K
LVS icon
405
Las Vegas Sands
LVS
$30.5B
$1.46M 0.04%
25,415
-85,211
-77% -$4.39M
GWPH
406
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.46M 0.04%
11,000
-5,000
-31% -$478K
CHRW icon
407
C.H. Robinson
CHRW
$22B
$1.45M 0.03%
20,513
-6,005
-23% -$421K
MCO icon
408
Moody's
MCO
$81.7B
$1.44M 0.03%
13,273
+4,633
+54% +$487K
ICE icon
409
Intercontinental Exchange
ICE
$82.4B
$1.44M 0.03%
26,640
-3,290
-11% -$180K
TTPH
410
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.43M 0.03%
18,700
PLD icon
411
Prologis
PLD
$138B
$1.43M 0.03%
26,635
+5,010
+23% +$264K
TXNM
412
TXNM Energy Inc
TXNM
$6.47B
$1.42M 0.03%
43,522
+31,854
+273% +$1.07M
MACK
413
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.42M 0.03%
28,470
+889
+3% +$36.9K
ROP icon
414
Roper Technologies
ROP
$36.3B
$1.42M 0.03%
7,762
+5,597
+259% +$976K
XLNX
415
DELISTED
Xilinx Inc
XLNX
$1.4M 0.03%
25,803
+3,688
+17% +$190K
AVXS
416
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.4M 0.03%
34,000
-14,000
-29% -$532K
NEM icon
417
Newmont
NEM
$98.2B
$1.39M 0.03%
35,402
+7,424
+27% +$308K
CKEC
418
DELISTED
Carmike Cinemas Inc
CKEC
$1.39M 0.03%
42,525
-2,475
-6% -$78K
MDRX
419
DELISTED
Veradigm Inc. Common Stock
MDRX
$1.38M 0.03%
+105,000
New +$1.4M
GBT
420
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.38M 0.03%
60,000
+25,000
+71% +$476K
REG icon
421
Regency Centers
REG
$15B
$1.38M 0.03%
17,805
+2,706
+18% +$219K
AVDL
422
DELISTED
Avadel Pharmaceuticals
AVDL
$1.38M 0.03%
111,000
DNB
423
DELISTED
Dun & Bradstreet
DNB
$1.37M 0.03%
10,028
-2,055
-17% -$275K
ED icon
424
Consolidated Edison
ED
$41.6B
$1.35M 0.03%
17,933
+4,619
+35% +$359K
FRT icon
425
Federal Realty Investment Trust
FRT
$10.9B
$1.33M 0.03%
8,652
+5,042
+140% +$815K

Similar funds

Candriam SCA's Q3 2016 Portfolio in Review

As of Q3 2016, Candriam SCA held 702 positions worth $4.16B, up 8.1% from $3.85B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Candriam SCA's Q3 2016 filing shows 49 new, 376 increased, 176 reduced and 46 closed positions. Its largest new stake was Zions Bancorporation: 362,062 shares worth $11.2M. The largest sale was Procter & Gamble, an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 25% a quarter earlier, followed by Financials and Technology.

  • Candriam SCA's largest Q3 2016 buy was Zions Bancorporation: 362,062 shares worth $11.2M.
  • Candriam SCA added most to Canadian National Railway in Q3 2016, an estimated $30.2M increase.
  • Candriam SCA's biggest Q3 2016 reduction was Procter & Gamble, cutting an estimated $26.9M.
  • Candriam SCA fully exited EMC CORPORATION in Q3 2016, selling an estimated $19.1M.
  • Candriam SCA's ten largest holdings make up 18% of its $4.16B portfolio in Q3 2016.
  • Candriam SCA opened 49 new positions and closed 46 in Q3 2016.
  • Candriam SCA's portfolio value rose 8.1% quarter-over-quarter to $4.16B.

Based on Candriam SCA's 13F filing for Q3 2016, filed 15 Nov 2016.